F.D.A. fällt entscheidung zu Avastin

Die amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) hat am Freitag (18.11.11) die Zulassung von Avastin zur Behandlung von Brustkrebs zurückgezogen. „The commissioner, Dr. Margaret A. Hamburg, said that clinical trials had shown that the drug was not helping breast cancer patients to live longer or to meaningfully control their tumors, but did expose them to potentially serious side effects like severe high blood pressure … F.D.A. fällt entscheidung zu Avastin weiterlesen